Association between β-blocker dose and quality of life after myocardial infarction: a real-world Swedish register-linked study.

ABSTRACT:

Background

β-blockers are routinely administered to patients following myocardial infarction (MI), yet their potential effect on health-related quality of life (HRQoL) is not entirely understood. We investigated the relationship between two different doses of β-blockers with HRQoL following MI.

Methods and results

This nationwide observational study used Swedish national registries to collate sociodemographic, clinical, medication, and HRQoL {the latter operationalized using EuroQol [European Quality of Life Five Dimensions Questionnaire (EQ-5D)]}. Estimates at 6-10 weeks and 12-14 months post-MI follow-up from pooled linear and logistic models were calculated after multiple imputation. We identified 35 612 patients with first-time MI, discharged with β-blockers, and enrolle

SUBMITTER: Humphries S 

PROVIDER: S-EPMC9216501 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature